A pharmaceuticals company will have to cut dramatically the price of an epilepsy drug after losing its legal action against the competition watchdog.
Flynn Pharma had previously been fined £5.2 million by the Competition and Markets Authority after the price of phenytoin sodium capsules that it sold rose by 2,600 per cent.
Pfizer, which manufactured the capsules and struck a deal with Flynn prior to the price rise, was fined a record £84.2 million as part of the same CMA decision.
In a hearing last week, Flynn asked the Competition Appeal Tribunal to suspend the CMA’s ruling that it had to decrease the price of the medicine by today because it plans to file an appeal against the watchdog’s decision.
Full Content: The Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition – Year of the Dragon
Apr 16, 2024 by
CPI
Review Logic and Rules for Concentrations of Undertakings that Do Not Meet the Standard of Notification
Apr 16, 2024 by
CPI
China’s Review of Semiconductor Transactions
Apr 16, 2024 by
CPI
Key Challenges and Tips for Merger Control Filing in China for Listed Companies
Apr 16, 2024 by
CPI
Key Point Review: China SPC Antitrust Judgments in 2023
Apr 16, 2024 by
CPI